Sign In
Buy DVAX
$15.50
+0 (+0%)
At Close: May 08, 2026
Dynavax Technologies Corporation (DVAX) Q3 2022 Earnings Call Transcript
08:32pm, Thursday, 03'rd Nov 2022
Dynavax Technologies Corporation (NASDAQ:DVAX ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Nicole Arndt - Senior Manager, IR Ryan Spencer - CEO Donn Casale - SVP
Intercept (ICPT) Q3 Earnings Miss, Sales Beat, View Raised
03:38pm, Wednesday, 02'nd Nov 2022 Zacks Investment Research
Intercept (ICPT) posts a wider loss in Q3 due to a loss on extinguishment of debt but beats on sales. Management increases annual sales guidance.
Gilead (GILD) Q3 Earnings & Sales Top, Guidance Raised
05:06pm, Friday, 28'th Oct 2022 Zacks Investment Research
Gilead (GILD) Q3 earnings and sales beat on strong HIV and oncology business. The company also raises its annual guidance.
Bristol-Myers (BMY) Q3 Earnings Beat, Sales Decline Y/Y
04:19pm, Wednesday, 26'th Oct 2022 Zacks Investment Research
Bristol-Myers' (BMY) third-quarter 2022 earnings beat estimates while sales miss the same due to a decline in sales of Revlimid.
Novartis (NVS) Q3 Earnings Top, Revenues Miss Estimates
04:14pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Novartis (NVS) reports mixed results for the third quarter as key brands maintain momentum but generic competition remains a drag.
Dynavax Technologies (DVAX) Recently Broke Out Above the 50-Day Moving Average
01:30pm, Tuesday, 25'th Oct 2022 Zacks Investment Research
Good things could be on the horizon when a stock surpasses the 50-Day simple moving average. How should investors react?
Dynavax Technologies (DVAX) Crossed Above the 20-Day Moving Average: What That Means for Investors
01:35pm, Monday, 24'th Oct 2022 Zacks Investment Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Dynavax Technologies (DVAX) Crossed Above the 20-Day Moving Average: What That Means for Investors
12:03pm, Monday, 24'th Oct 2022
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
Does Dynavax Technologies (DVAX) Have the Potential to Rally 210% as Wall Street Analysts Expect?
01:55pm, Friday, 21'st Oct 2022 Zacks Investment Research
The mean of analysts' price targets for Dynavax Technologies (DVAX) points to a 210.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement
Should Value Investors Buy Dynavax Technologies (DVAX) Stock?
01:40pm, Thursday, 20'th Oct 2022 Zacks Investment Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Should Value Investors Buy Dynavax Technologies (DVAX) Stock?
11:19am, Thursday, 20'th Oct 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
The 7 Most Undervalued Long-Term Stocks to Buy Now
12:18pm, Wednesday, 19'th Oct 2022
My task today is to find seven of the most undervalued long-term stocks to buy now. We need to determine two things before stock selection takes place.
Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related Sales
05:20pm, Tuesday, 18'th Oct 2022 Zacks Investment Research
Roche's (RHHBY) performance in the third quarter was pretty ho-hum as COVID-19-related sales continue to decline.
Regeneron (REGN) Drug Gets Positive CHMP View for Cervical Cancer
05:36pm, Monday, 17'th Oct 2022 Zacks Investment Research
Regeneron (REGN) gets a positive recommendation from CHMP for the label expansion of its oncology drug for treating adult patients with recurrent or metastatic cervical cancer.
Novartis' (NVS) Pluvicto Secures Positive CHMP Opinion
04:08pm, Monday, 17'th Oct 2022 Zacks Investment Research
Novartis (NVS) radioligand therapy Pluvicto gets positive recommendation by the CHMP for patients with progressive, PSMA-positive metastatic castration-resistant prostate cancer.
